Clinical Trial Update: A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

A Phase III randomized trial comparing low-dose versus standard-dose mBACOD chemotherapy with rGM-CSF for AIDS-associated non-Hodgkin lymphoma has been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Non-hodgkin Lymphoma

Drugs mentioned

• mBACOD (mBACOD)
• rGM-CSF (recombinant granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lymphoma, Non-Hodgkin, HIV Infections | Phase 3 | Status: COMPLETED